REG - IXICO plc - Director/PDMR Shareholding

IXICOAnnouncement

16/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241016:nRSP3223Ia&default-theme=true

RNS Number : 3223I  IXICO plc  16 October 2024

16 October 2024

 

 

IXICO plc

("IXICO" or the "Company")

 

Director/PDMR Shareholding

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience, announces that it has been notified that
on 15 October 2024, Robin Wolz, Chief Scientific Officer and a PDMR of the
Company, purchased 44,000 ordinary shares of 1 pence each in the capital of
the Company ("Ordinary Shares") at an average price of 9.91* pence per
Ordinary Share.

As a result, Robin Wolz is now interested in a total of 44,000 Ordinary
Shares, representing 0.09% of the Company's issued share capital.

The information below, set out in accordance with the requirements of the UK
Market Abuse Regulation, provides further detail.

* The tranactions took place on the Frankfurt Boerse at an average price of
0.119076 EUR and has been converted at the closing middle market spot price of
0.83 GBP:EUR.

 

- Ends -

 

For further information please contact:

 

 IXICO plc                                          +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated adviser and sole broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)
 Nigel Birks (Life Sciences Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

 

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Robin Wolz

 2    Reason for the notification

 a)   Position/status                                              Chief Scientific Officer and PDMR

 b)   Initial notification /Amendment                              Initial

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         IXICO plc

 b)   LEI                                                          2138005M1F59O6HWSA97

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares in IXICO plc

      Identification code                                          ISIN: GB00BFXR4C20

 b)   Nature of the transaction                                    Acquisition of Ordinary shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.114542 EUR      10,000
                                                                                     0.120713 EUR      9,000
                                                                                     0.1203 EUR        25,000

 d)   Aggregated information

      - Aggregated volume                                          44,000 shares

      - Price                                                      0.119076 EUR

 e)   Date of the transaction                                      15 October 2024

 f)   Place of the transaction                                     Frankfurt (Germany)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBELLFZBLLFBD